122 related articles for article (PubMed ID: 37944697)
1. Dual anti-viral treatment for persistent COVID-19 in immunocompromised hemato-oncological patients is associated with a favorable prognosis and minor side effects.
Meijer SE; Halutz O; Adler A; Levytskyi K; Tau L; Dekel M; Cohen-Poradosu R; Katchman E; Shasha D; Ablin J; Choshen G; Jacob G; Wasserman A; Ingbir M; Cohen YC; Perry C; Ram R; Herishanu Y; Bar On Y; van Thijn E; Rutsinsky N; Harari S; Stern A; Ben-Ami R; Paran Y
J Infect Chemother; 2024 Mar; 30(3):271-275. PubMed ID: 37944697
[TBL] [Abstract][Full Text] [Related]
2. Dual combined antiviral treatment with remdesivir and nirmatrelvir/ritonavir in patients with impaired humoral immunity and persistent SARS-CoV-2 infection.
Pasquini Z; Toschi A; Casadei B; Pellegrini C; D'Abramo A; Vita S; Beccacece A; Bussini L; Chionsini MC; Dentale N; Cantiani A; Lazzarotto T; Bartoletti M; Nicastri E; Zinzani P; Giannella M; Viale P
Hematol Oncol; 2023 Dec; 41(5):904-911. PubMed ID: 37452579
[TBL] [Abstract][Full Text] [Related]
3. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
[TBL] [Abstract][Full Text] [Related]
4. Triple Combination Therapy With 2 Antivirals and Monoclonal Antibodies for Persistent or Relapsed Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients.
Mikulska M; Sepulcri C; Dentone C; Magne F; Balletto E; Baldi F; Labate L; Russo C; Mirabella M; Magnasco L; Di Grazia C; Ghiggi C; Raiola AM; Giacobbe DR; Vena A; Beltramini S; Bruzzone B; Lemoli RM; Angelucci E; Bassetti M
Clin Infect Dis; 2023 Jul; 77(2):280-286. PubMed ID: 36976301
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment of persisting SARS-CoV-2 infection in an immunocompromised patient with repeated nirmatrelvir/ritonavir courses: a case report.
Lindahl AL; Ahava MJ; Haukipää M; Kreivi HR; Lipponen A; Kortela E
Infect Dis (Lond); 2023 Aug; 55(8):585-589. PubMed ID: 37334428
[TBL] [Abstract][Full Text] [Related]
6. Successful treatment of persistent SARS-CoV-2 infection with nirmatrelvir/ritonavir plus sotrovimab in four immunocompromised patients.
Lanzafame M; Gottardi M; Guella L; Collini L; Costa G; Guella A; Vento S
J Chemother; 2023 Nov; 35(7):623-626. PubMed ID: 37102326
[TBL] [Abstract][Full Text] [Related]
7. Remdesivir or Nirmatrelvir/Ritonavir Therapy for Omicron SARS-CoV-2 Infection in Hematological Patients and Cell Therapy Recipients.
Piñana JL; Heras I; Aiello TF; García-Cadenas I; Vazquez L; Lopez-Jimenez J; Chorão P; Aroca C; García-Vidal C; Arroyo I; Soler-Espejo E; López-Corral L; Avendaño-Pita A; Arrufat A; Garcia-Gutierrez V; Arellano E; Hernández-Medina L; González-Santillana C; Morell J; Hernández-Rivas JÁ; Rodriguez-Galvez P; Mico-Cerdá M; Guerreiro M; Campos D; Navarro D; Cedillo Á; Martino R; Solano C;
Viruses; 2023 Oct; 15(10):. PubMed ID: 37896843
[TBL] [Abstract][Full Text] [Related]
8. High-titer convalescent plasma plus nirmatrelvir/ritonavir treatment for non-resolving COVID-19 in six immunocompromised patients.
Huygens S; Gharbharan A; Serroukh Y; Snoek B; Franken B; Oude Munnink BB; Van Hagen PM; Bogers S; Geurtsvankessel CH; Rijnders BJA
J Antimicrob Chemother; 2023 Jul; 78(7):1644-1648. PubMed ID: 37248664
[TBL] [Abstract][Full Text] [Related]
9. Remdesivir for the treatment of COVID-19.
Ansems K; Grundeis F; Dahms K; Mikolajewska A; Thieme V; Piechotta V; Metzendorf MI; Stegemann M; Benstoem C; Fichtner F
Cochrane Database Syst Rev; 2021 Aug; 8(8):CD014962. PubMed ID: 34350582
[TBL] [Abstract][Full Text] [Related]
10. Persistent SARS-CoV-2 PCR Positivity Despite Anti-viral Treatment in Immunodeficient Patients.
Chan M; Linn MMN; O'Hagan T; Guerra-Assunção JA; Lackenby A; Workman S; Dacre A; Burns SO; Breuer J; Hart J; Tadros S; Lowe DM
J Clin Immunol; 2023 Aug; 43(6):1083-1092. PubMed ID: 37148422
[TBL] [Abstract][Full Text] [Related]
11. Combination regimen of nirmatrelvir/ritonavir and molnupiravir for the treatment of persistent SARS-CoV-2 infection: A case report and a scoping review of the literature.
Marangoni D; Antonello RM; Coppi M; Palazzo M; Nassi L; Streva N; Povolo L; Malentacchi F; Zammarchi L; Rossolini GM; Vannucchi AM; Bartoloni A; Spinicci M
Int J Infect Dis; 2023 Aug; 133():53-56. PubMed ID: 37150351
[TBL] [Abstract][Full Text] [Related]
12. Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial.
Schilling WHK; Jittamala P; Watson JA; Boyd S; Luvira V; Siripoon T; Ngamprasertchai T; Batty EM; Cruz C; Callery JJ; Singh S; Saroj M; Kruabkontho V; Ngernseng T; Tanglakmankhong N; Tubprasert J; Abdad MY; Madmanee W; Kouhathong J; Suwannasin K; Pagornrat W; Piaraksa N; Hanboonkunupakarn P; Hanboonkunupakarn B; Poovorawan K; Potaporn M; Srisubat A; Loharjun B; Taylor WRJ; Chotivanich V; Chotivanich K; Imwong M; Pukrittayakamee S; Dondorp AM; Day NPJ; Teixeira MM; Piyaphanee W; Phumratanaprapin W; White NJ;
Lancet Infect Dis; 2024 Jan; 24(1):36-45. PubMed ID: 37778363
[TBL] [Abstract][Full Text] [Related]
13. Synergistic Activity of Remdesivir-Nirmatrelvir Combination on a SARS-CoV-2 In Vitro Model and a Case Report.
Gidari A; Sabbatini S; Schiaroli E; Bastianelli S; Pierucci S; Busti C; Saraca LM; Capogrossi L; Pasticci MB; Francisci D
Viruses; 2023 Jul; 15(7):. PubMed ID: 37515263
[TBL] [Abstract][Full Text] [Related]
14. Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study.
Wong CKH; Au ICH; Lau KTK; Lau EHY; Cowling BJ; Leung GM
Lancet Infect Dis; 2022 Dec; 22(12):1681-1693. PubMed ID: 36029795
[TBL] [Abstract][Full Text] [Related]
15. [Related factors of viral nucleic acid change in critically ill patients with SARS-CoV-2 infection after treatment with Nirmatrelvir/Ritonavir: a single center retrospective cohort study].
Yan M; Xie M; Zhu S; Li H; Li S
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2023 Nov; 35(11):1150-1156. PubMed ID: 37987124
[TBL] [Abstract][Full Text] [Related]
16. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
[TBL] [Abstract][Full Text] [Related]
17. Viral burden rebound in hospitalised patients with COVID-19 receiving oral antivirals in Hong Kong: a population-wide retrospective cohort study.
Wong CKH; Lau KTK; Au ICH; Lau EHY; Poon LLM; Hung IFN; Cowling BJ; Leung GM
Lancet Infect Dis; 2023 Jun; 23(6):683-695. PubMed ID: 36796397
[TBL] [Abstract][Full Text] [Related]
18. Persistent replication of SARS-CoV-2 in a severely immunocompromised patient treated with several courses of remdesivir.
Camprubí D; Gaya A; Marcos MA; Martí-Soler H; Soriano A; Mosquera MDM; Oliver A; Santos M; Muñoz J; García-Vidal C
Int J Infect Dis; 2021 Mar; 104():379-381. PubMed ID: 33359065
[TBL] [Abstract][Full Text] [Related]
19. Case report study of the first five COVID-19 patients treated with remdesivir in France.
Dubert M; Visseaux B; Isernia V; Bouadma L; Deconinck L; Patrier J; Wicky PH; Le Pluart D; Kramer L; Rioux C; Le Hingrat Q; Houhou-Fidouh N; Yazdanpanah Y; Ghosn J; Lescure FX
Int J Infect Dis; 2020 Sep; 98():290-293. PubMed ID: 32619764
[TBL] [Abstract][Full Text] [Related]
20. Optimizing COVID-19 treatment in immunocompromised patients: early combination therapy with remdesivir, nirmatrelvir/ritonavir and sotrovimab.
Gentile I; Foggia M; Silvitelli M; Sardanelli A; Cattaneo L; Viceconte G
Virol J; 2023 Dec; 20(1):301. PubMed ID: 38102675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]